Indian CDSCO logo vs CE/FDA stamp and text overlay: “₹2,000 Crore Hypocrisy: Why India Buys Foreign Over Indian Standards”

 

CDSCO vs CE/FDA: The Great Tender Trap That’s Killing Make in India

By Ankur K. Khare – Biomedical Engineer | AI Ethics & Medical Innovation




The ₹2,000 Crore Hypocrisy Nobody Talks About

India’s medical device revolution is being strangled by its own procurement rules. Despite having world-class CDSCO standards, government tenders still worship foreign CE/FDA approvals — sabotaging the very vision of Atmanirbhar Bharat.

While Prime Minister Modi passionately advocates “Make in India” and “Atmanirbhar Bharat,” a silent bureaucratic conspiracy is dismantling that very vision from within.

Across India, government tenders still demand CE/FDA certifications for medical devices — even when Indian manufacturers already have CDSCO approvals, our own regulatory gold standard.

This isn’t just a policy oversight — it’s institutional sabotage of national self-reliance.


The CGMSC Tender: Bureaucratic Betrayal in Action

The recent CGMSC tender for Electro-Mechanical OT Tables is a perfect example of how Indian innovators are systematically excluded.

What the tender demanded:

  • “European CE/USFDA certification required as according to the product”

  • BIS and IEC certifications required

  • Zero mention of Make in India preference

  • CDSCO approval buried as an afterthought

What it should have demanded:

  • CDSCO approval as primary requirement

  • BIS certification where applicable

  • CE/FDA only if Indian standards don’t exist

  • Clear Make in India preference with 20% price advantage


Government’s Own Rules — Ignored by Its Own System

Despite clear directives from multiple ministries, tenders continue to favor foreign certifications.

Ministry of Health & Family Welfare (Feb 20, 2018):

“Where Indian Standards are available, BIS/CDSCO/AERB are sufficient. Organizations shall not insist on foreign certifications like CE or USFDA.”

NHSRC Advisory (July 24, 2018):

“US FDA/CE requirements will apply only when Indian standards like BIS/CDSCO/AERB are not available.”

Department of Pharmaceuticals (May 18, 2018):

  • 50% minimum local content for medical disposables

  • 25% for medical electronics & instruments

  • 40% for implants

Yet, these policies are routinely violated with impunity.


The Numbers Don’t Lie: Import Dependence by Design

India’s medical device market: ₹75,000 crore ($11 billion)

Imports: 85% of devices

Indian manufacturers’ share: 15%

Jobs lost: 2.5 lakh direct opportunities

Government procurement: ₹15,000+ crore annually

➡️ 70% goes to foreign brands due to tender bias

➡️ Indian R&D investments rendered worthless


The Cost of Policy Sabotage

Direct Economic Losses:

  • ₹65,000 crore foreign exchange outflow annually

  • ₹12,000 crore lost tax revenue (GST + customs)

  • ₹5,000 crore wasted in Indian R&D efforts

Human & Strategic Costs:

  • 2.5 lakh direct and 7.5 lakh indirect job losses

  • 85% dependence on foreign supply chains during crises

  • Stagnant domestic innovation

  • Weak national health security

This isn’t inefficiency — it’s a designed dependency.


The Way Forward: Implement True Atmanirbhar Procurement

Immediate Actions:

  1. Audit all active tenders — cancel those violating Make in India policy

  2. Train 5,000+ procurement officers in domestic preference rules

  3. Standardize tender templates prioritizing Indian certifications

Structural Reforms:

  • Regulatory clarity: Declare CDSCO as sufficient for Indian tenders

  • Procurement accountability: Establish a Medical Device Procurement Tribunal

  • Innovation support: Create a regulatory sandbox for emerging MedTech


The Call to Action

For Policymakers:

  • Issue urgent circular mandating CDSCO-first procurement

  • Enforce accountability for Make in India violations

For Industry:

  • Document & report every biased tender

  • Build an Indian MedTech coalition for collective legal action

For Citizens:

  • Ask hospitals about their procurement sources

  • Choose Indian-approved devices where possible

  • Demand policy compliance from public institutions


The Bottom Line: Atmanirbhar Bharat or Atmanirbhar Illusion?

Every CE/FDA-only tender is a nail in the coffin of Indian innovation.

Every excluded Indian manufacturer is a blow to national self-reliance.

We can’t build an Atmanirbhar Bharat on imported standards.

India doesn’t lack innovation — it lacks recognition for its own standards.

The choice is stark:
Continue the hypocrisy, or commit to genuine Atmanirbhar procurement.

Prime Minister Modi’s vision will remain a slogan — unless we fix the tender trap that kills Indian manufacturing.

The future of Indian healthcare depends on it.
                                        Choose wisely. Choose CDSCO. Choose India. 


Comments

Post a Comment

Popular posts from this blog

The ₹50 Lakh Mistake Killing Indian MedTech Startups — And How to Avoid It

The One Regulatory Mistake That Costs Indian MedTech Startups ₹50 Lakh and 2 Years — And How to Avoid It By Ankur Khare — Biomedical Engineer | Regulatory Affairs Specialist | Founder- MedReg Intel There is a mistake so common in Indian MedTech startups that I have started calling it the Silent Killer of early stage medical device companies. It does not show up in your pitch deck. Your investors will not catch it. Your product team will not flag it. Even your legal counsel may miss it — unless they have specific medical device regulatory experience. By the time most startups discover this mistake, they have already spent ₹30 to ₹50 lakh in product development, hired a team, signed letters of intent with hospital procurement departments, and told their investors they are six months from launch. Then CDSCO sends a deficiency notice. Or worse — a rejection. And suddenly those six months become two years. This article is about that mistake. What it is, why it keeps happening, what ...
Read more

A Practical Roadmap for Developing Medical Devices in India

A Practical Roadmap for Developing Medical Devices in India From Idea to Market — Without Costly Regulatory Mistakes By Ankur K. Khare – Biomedical Engineer | Regulatory Affairs Specialist | AI Ethics & Medical Innovation Developing a medical device in India is not just an engineering challenge. It is a regulatory, clinical, manufacturing, and ethical journey — and most failures happen not because the product is bad, but because the roadmap is wrong . Too many teams build first and think about regulation later. By the time CDSCO enters the picture, timelines are already broken. This guide lays out a clear, India-specific roadmap for medical device development — grounded in MDR 2017, CDSCO scrutiny patterns, and real-world failures — so teams can build right , not just fast. Why This Matters An incorrect development sequence can: Delay approvals by months Multiply compliance costs Force redesigns late in the lifecycle Undermine regulatory credibility Most of this is preventable —...
Read more

How to Classify Medical Devices in India (Class A, B, C & D) – MDR 2017 Guide

Medical Device Classification in India Class A, B, C & D — Practically Explained Under MDR 2017 By Ankur K. Khare – Biomedical Engineer | Regulatory Affairs Specialist | AI Ethics & Medical Innovation Medical device classification in India is not paperwork. It is the single decision that determines: Your regulatory pathway Your documentation burden Your clinical evidence requirements Your approval timelines Your compliance cost Under the Medical Device Rules (MDR), 2017 , every medical device is classified into Class A, B, C, or D based on risk. Misclassify your device — and everything downstream becomes unstable. This article explains classification practically , not just legally. Why Classification Matters More Than You Think Your classification affects: Whether you apply to State or Central authority Which forms you submit (MD-5, MD-9, MD-14, etc.) Whether clinical investigation is required How intense CDSCO scrutiny will be Post-market obligations ⚠️ Common Founder Mistake...
Read more